New hope for new moms: early access to postpartum depression treatment
NCT ID NCT03924492
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This program offers early access to ZULRESSO (brexanolone) for a limited number of women with postpartum depression before the drug is widely available. Eligible participants are adult women diagnosed with postpartum depression who agree to the program's requirements. The goal is to provide treatment to those who may benefit while the drug is being prepared for commercial use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTPARTUM DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.